Sogroya Injection, Solution
Product Images NDC 0169-2035

Product Visual Gallery

This gallery contains 91 technical images submitted to the FDA as part of the official labeling for Sogroya (NDC 0169-2035). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novo Nordisk, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of 10 mg Carton (Image 01)

An instructional illustration depicting a hand holding a subcutaneous injection pen needle near a forearm, with an arrow pointing downward toward the skin, indicating the injection direction. A small device or meter is shown nearby on the right side.*

FDA Label Image

Image Of Molecule Structure (Image 02)

Chemical structure diagram showing the peptide sequence and molecular structure of somapacitan-beco, the active ingredient in SOGROYA injection solution by Novo Nordisk.*

FDA Label Image

Front Cover Page (illustration of Sogroya Pen)

FDA Label Image

Illustration Of Sogroya Pen Components. (Image 04)

FDA Label Image

Illustration Of Needle Components (Image 05)

SOGROYA 10 mg/1.5 mL (6.7 mg/mL) injection, solution for subcutaneous use. The label shows the product name and strength with a design featuring yellow and gray colors and the Novo Nordisk logo. This is a human prescription drug by Novo Nordisk.*

FDA Label Image

Figure K: Example Of 1.5 mg Selected (Image 06)

Illustration of a SOGROYA Pen for subcutaneous injection of somapacitan-beco. The pen is labeled showing key parts including the pen window, dose counter, dose pointer, dose selector, dose button, and pen scale. The pen body features the Sogroya name and concentration information.*

FDA Label Image

Back Cover Page. Illustration Of Sogroya Pen. (Image 07)

Instructions for Use for SOGROYA (somapacitan-beco) injection, 10 mg/1.5 mL (6.7 mg/mL), by Novo Nordisk. The image shows a pen injector device for subcutaneous administration, highlighting the dosing frequency of one time each week. The Novo Nordisk logo appears at the bottom.*

FDA Label Image

Image 08

Label for SOGROYA injection showing the proprietary name and strength as 5 mg per 1.5 mL (3.3 mg/mL) somapacitan-beco solution. The label includes the Novo Nordisk logo, states subcutaneous administration, and indicates a dosing frequency of one time each week.*

FDA Label Image

Image 09

Illustration of the SOGROYA pen for somapacitan-beco injection, showing labeled components including the pen window, pen scale, dose counter, dose pointer, dose selector, and dose button. The pen displays dosage information of 5 mg/1.5 mL (3.3 mg/mL).*

FDA Label Image

Image 10

An illustration showing a close-up side view of the pen cap of a prefilled injection pen device for the drug SOGROYA (somapacitan-beco). The pen cap is labeled with the text "Pen cap" indicating its part.*

FDA Label Image

Image 11

An instructional illustration showing labeled parts of a needle, including the outer needle cap, inner needle cap, needle, and paper tab. The diagram provides a visual example of these components for user reference.*

FDA Label Image

Image 12

An instructional illustration showing a medicine vial outline alongside a subcutaneous injection pen labeled SOGROYA, solution for injection. The image also includes components likely used for injection preparation: a vial cap, a protective cover, and a needle cap, indicating parts of the drug administration process for subcutaneous use.*

FDA Label Image

Supplies You Will Need (Image 13)

An illustration showing a close-up view of the yellow pen cap component of a drug injection device, labeled as "Pen cap." This is likely part of the SOGROYA (somapacitan-beco) injection delivery system by Novo Nordisk.*

FDA Label Image

Important Information Symbol (Image 14)

SOGROYA injection solution carton by Novo Nordisk, showing the proprietary name SOGROYA and the generic name somapacitan-beco. The label indicates available strengths of 10 mg/mL, 3.3 mg/mL, and 6.7 mg/mL for subcutaneous use. The packaging features a predominantly white and blue design with dosage strength and labeler information.*

FDA Label Image

Additional Information Symbol (Image 15)

SOGROYA injection, solution, featuring three available strengths indicated on the label: 10 mg/mL, 3.3 mg/mL, and 6.7 mg/mL. This product is a human prescription drug containing somapacitan-beco for subcutaneous administration. The label includes the Novo Nordisk logo and branding details.*

FDA Label Image

Figure A Turn Pen Upside Down (Image 16)

An instructional diagram illustrating the components of a needle assembly example for subcutaneous injection. It shows four parts labeled from left to right: outer needle cap, inner needle cap, needle, and paper tab, demonstrating the sequence and identification of these elements.*

FDA Label Image

Figure B Push The Needle Straight On (Image 17)

SOGROYA is shown as a subcutaneous injection solution containing somapacitan-beco with strengths of 10 mg/mL, 3.3 mg/mL, and 6.7 mg/mL. The image includes a vial, a pen injector device, a small foil packet, and an injection needle cap. The product is labeled by Novo Nordisk.*

FDA Label Image

Important Information Symbol (Image 18)

FDA Label Image

Figure C Pull Off Outer Needle Cap And Dispose Of It (Image 19)

An instructional diagram showing a close-up of a hand holding a Sogroya injection pen, specifically the yellow dosage selector or dial area, likely illustrating usage or dosage adjustment for the somapacitan-beco subcutaneous injection.*

FDA Label Image

Figure D Pull Off Inner Needle Cap And Dispose Of It (Image 20)

An instructional diagram showing a close-up of a hand holding a pen-style injection device. The image focuses on the thumb turning a yellow dial or knob on the device, indicating a twisting or adjustment motion.*

FDA Label Image

Additional Information Symbol (Image 21)

The image shows the packaging label for SOGROYA (somapacitan-beco) injection, solution, intended for subcutaneous use. The label includes product strength options of 3.3 mg/mL, 6.7 mg/mL, and 10 mg/mL. The labeler is Novo Nordisk. The packaging features dosage and safety information and branding elements consistent with prescription drug labeling.*

FDA Label Image

Important Information Symbol (Image 22)

SOGROYA 10 mg/mL injection solution in a 3 mL glass vial with a gray rubber stopper and aluminum seal. Label includes drug name, concentration, and administration route (subcutaneous), with branding and regulatory details from Novo Nordisk.*

FDA Label Image

Figure E Turn Dose Selector Clockwise (Image 23)

FDA Label Image

Figure F 1 Marking On Dose Counter Equals 0.05 mg. (Image 24)

An instructional illustration showing a hand holding a pen injection device with an arrow indicating twisting or unscrewing the cap. An inset zooms in on the cap removal step, guiding proper preparation before subcutaneous injection.*

FDA Label Image

Figure G Hold The Pen With The Needle Pointing Up (Image 25)

An instructional diagram showing a hand pressing a button on a pen-type subcutaneous injection device, with an inset indicating the direction of the push. This image likely demonstrates part of the usage steps for administering SOGROYA injection solution.*

FDA Label Image

Figure H Check That A Drop Appears At The Needle Tip (Image 26)

An instructional illustration showing hands operating a SOGROYA injection pen. The image highlights adjusting or setting the dose on the pen, indicated by an arrow pointing to the dose display window on the device.*

FDA Label Image

Important Information Symbol (Image 27)

Illustration showing the dose setting window of a SOGROYA (somapacitan-beco) injection pen, highlighting the dial display indicating a dose of 0.1 mg. The device is dark-colored with a rotating dial used to adjust the subcutaneous injection dosage.*

FDA Label Image

Important Information Symbol (Image 28)

SOGROYA 10 mg/mL injection, solution in a subcutaneous delivery form. The image shows a clear glass vial with a white label featuring blue and black text displaying the product name, strength, and dosage form. The vial is capped with a gray and blue stopper. Manufactured by Novo Nordisk.*

FDA Label Image

Important Information Symbol (Image 29)

FDA Label Image

Additional Information Symbol (Image 30)

SOGROYA (somapacitan-beco) injection, solution in a 3.3 mg/mL strength vial for subcutaneous use. The glass vial contains a clear liquid and is labeled with the proprietary name, strength, and manufacturer Novo Nordisk. The vial cap is teal-colored.*

FDA Label Image

Additional Information Symbol (Image 31)

SOGROYA 6.7 mg/mL injection solution in a 3 mL multi-dose cartridge for subcutaneous use. The label displays the brand name, strength, dosage form, and manufacturer Novo Nordisk. The cartridge contains 20 mg of somapacitan-beco and includes dosing and storage instructions visible on the label.*

FDA Label Image

Additional Information Symbol (Image 32)

SOGROYA injection, solution in a vial, labeled with 3.3 mg/mL strength of somapacitan-beco. The vial is glass with a white, red, and orange label including the product name, strength, and dosage form. The labeler is Novo Nordisk.*

FDA Label Image

Additional Information Symbol (Image 33)

The image shows the SOGROYA 6.7 mg/mL injection solution carton for subcutaneous use. The packaging features the Novo Nordisk labeler name and lists the drug's generic name somapacitan-beco. The box design includes branding and dosage strength clearly visible on the front panel.*

FDA Label Image

Additional Information Symbol (Image 34)

SOGROYA injection, solution in a 10 mg/mL strength vial is presented in the image. The vial is a small transparent glass container with a blue cap, containing a clear liquid. It features a label showing the product name SOGROYA and concentration, intended for subcutaneous administration, and is marketed by Novo Nordisk.*

FDA Label Image

Additional Information Symbol (Image 35)

SOGROYA injection solution carton by Novo Nordisk, showing the proprietary name SOGROYA prominently. The label includes generic name somapacitan-beco and lists strengths 3.3 mg/mL, 6.7 mg/mL, and 10 mg/mL. The label indicates the product is for subcutaneous administration and is a human prescription drug.*

FDA Label Image

Additional Information Symbol (Image 36)

SOGROYA injection, solution, in subcutaneous dosage form. The image shows a carton containing three different strengths: 10 mg/mL, 3.3 mg/mL, and 6.7 mg/mL. The labeler is Novo Nordisk, which is indicated on the packaging.*

FDA Label Image

Additional Information Symbol (Image 37)

SOGROYA injection, solution, available in 10 mg/mL strength, by Novo Nordisk. The label shows a white and purple color scheme with the product name SOGROYA prominently displayed and the generic name somapacitan-beco noted below. The label includes dosage information and details about the subcutaneous injection form.*

FDA Label Image

Image 38

FDA Label Image

Figure I Turn The Dose Selector Clockwise (Image 39)

An instructional illustration showing a hand holding a black cap with a white arrow pointing upward, indicating the removal or lifting of the cap. The image is part of a step-by-step guide likely related to preparing or using the SOGROYA (somapacitan-beco) injection solution.*

FDA Label Image

Figure J Example 2.95 Selected (Image 40)

An instructional diagram showing the top portion of a yellow and white injection device or pen. The image highlights the pen's cap with a small raised indicator or marker visible on the white component. The purpose appears to be related to the assembly or use of the injection device for the drug Somapacitan-beco.*

FDA Label Image

Image 41

SOGROYA injection, solution for subcutaneous use, available in strengths of 10 mg/mL, 6.7 mg/mL, and 3.3 mg/mL. The label includes the proprietary name SOGROYA, the generic name somapacitan-beco, and is labeled by Novo Nordisk. The packaging displays dosage strengths with distinct color-coded sections for each concentration.*

FDA Label Image

Figure L The Pen Clicks Sound And Feel Differently (Image 42)

An instructional illustration showing a person holding a SOGROYA injection pen labeled somapacitan-beco, with a close-up on the dose display window showing '10 mg'. The image includes an arrow indicating a rotational motion, likely demonstrating how to set or adjust the dose on the subcutaneous injection device.*

FDA Label Image

Figure M Injection Sites (Image 43)

An instructional illustration showing a front view of a human torso indicating the subcutaneous injection sites in the abdominal area, relevant for the administration of SOGROYA (somapacitan-beco) injection solution.*

FDA Label Image

Figure N Insert The Needle (Image 44)

An instructional diagram showing a hand holding an injection pen device vertically downward. The illustration indicates pressing down with an arrow to demonstrate the injection technique for a subcutaneous somapacitan-beco solution.*

FDA Label Image

Figure O Press And Hold Down The Dose Button (Image 45)

An instructional illustration showing a hand holding an injection pen vertically with a downward arrow above it, indicating the direction for use or injection. A close-up of the device's dose window is visible to the right, displaying a numeric dose indicator set at zero.*

FDA Label Image

Figure P Count Slowly To 6 (Image 46)

An instructional illustration showing a dosage selection window on an injectable device for SOGROYA (somapacitan-beco). The visible dosage displayed is 2.93 mg, with an example note indicating 2.95 mg selected. The device is designed for subcutaneous injection.*

FDA Label Image

Figure Q Remove The Needle From Your Skin (Image 47)

An instructional illustration showing the removal of a yellow needle cap from a syringe or injection pen. The image includes an upward pointing blue arrow indicating the direction to pull the cap off the needle.*

FDA Label Image

Figure R Place The Needle In A Sharps Container (Image 48)

An instructional illustration showing a hand twisting the cap off a small injection device or vial, indicated by a curved arrow pointing counterclockwise. A smaller inset reinforces the action of removing the cap by twisting, demonstrating preparation of the injection device for use.*

FDA Label Image

Figure S Put The Pen Cap On Your Pen (Image 49)

Illustration showing a dosing selection window on a SOGROYA injection pen, indicating an example dose of 1.5 mg selected for subcutaneous administration of somapacitan-beco solution.*

FDA Label Image

Figure T The Pen Scales Shows Approximately How Much Is Left (Image 50)

Instructional illustration showing hands holding a SOGROYA subcutaneous injection pen. The image highlights the dose window with an arrow pointing to the displayed dose of 25 mg, indicating how to check or set the injection dose on the pen device.*

FDA Label Image

Figure U Example 2.8 mg Left (Image 51)

Instructional illustration showing the proper technique for administering SOGROYA injection subcutaneously. The image depicts a hand holding the injection pen at a right angle to the skin, with a prompt to count slowly from 1 to 6 during injection.*

FDA Label Image

Image 52

An instructional illustration showing a hand holding a SOGROYA injection pen. The image highlights the pen's needle cover area, likely demonstrating part of the injection preparation or administration process for subcutaneous use of somapacitan-beco solution.*

FDA Label Image

Image 53

An instructional illustration showing hands holding and preparing a SOGROYA (somapacitan-beco) injection pen for subcutaneous use. The image depicts the step of attaching or aligning a component on the pen, indicated by a directional arrow.*

FDA Label Image

Image 54

An instructional illustration showing a hand operating a subcutaneous injection device, likely related to the SOGROYA (somapacitan-beco) injection. The image depicts the hand holding the injector and pressing a green part with a blue arrow indicating an upward motion, suggesting a step in preparing or administering the injection.*

FDA Label Image

Image 55

FDA Label Image

Image 56

An instructional illustration showing a hand gripping and twisting the cap of a pen injector device, with an arrow indicating the twisting motion. A small inset shows a close-up of the cap removal process. No text or branding is visible.*

FDA Label Image

Image 57

An instructional illustration showing a hand operating a medical pen device by pressing a button to prepare for injection, with an inset close-up highlighting the button pressing action. This is consistent with use instructions for subcutaneous injection devices like those for SOGROYA (somapacitan-beco).*

FDA Label Image

Image 58

FDA Label Image

Image 59

FDA Label Image

Image 60

FDA Label Image

Image 61

An instructional illustration showing two hands holding a dosing pen injector for SOGROYA (somapacitan-beco) injection. One hand grips the pen while the other adjusts the dose setting, indicated by a visible dose window on the device. Arrows suggest the direction for dose adjustment on the subcutaneous injection device.*

FDA Label Image

Image 62

Close-up illustration of the dosage window on a SOGROYA injector pen showing a dose setting dial with the display reading 0.05 mg. The pen is blue and gray, consistent with SOGROYA injection solution packaging for subcutaneous use by Novo Nordisk.*

FDA Label Image

Image 63

An instructional illustration showing a hand holding a small injector device labeled 'Eject 1,' with an upward-pointing arrow indicating to pull or lift the device upward. The image likely demonstrates part of the administration process for SOGROYA injection.*

FDA Label Image

Image 64

An illustration showing the top part of a subcutaneous injection device with a small needle visible at the tip. The device appears to be designed for administering SOGROYA (somapacitan-beco) injection solution, though no text or branding is visible in this close-up image.*

FDA Label Image

Image 65

FDA Label Image

Image 66

An instructional illustration showing hands holding a SOGROYA injection device. The image highlights a dose window on the device marked with '0.0 mg,' with an arrow indicating upward adjustment or dose setting on the subcutaneous injection pen.*

FDA Label Image

Image 67

FDA Label Image

Image 68

FDA Label Image

Image 69

Illustration of a dosage selection window on a SOGROYA (somapacitan-beco) injection pen, showing the dose setting at approximately 1.575 mg. The window displays incremental dosage markings, indicating precise dose adjustment capability for subcutaneous injection.*

FDA Label Image

Image 70

An illustration showing a dosage selection window on a pen injector displaying a dose of 1.5 mg. The image highlights how the dose amount is visible through a small window on the device.*

FDA Label Image

Image 71

FDA Label Image

Image 72

An instructional illustration showing two hands adjusting a dose on an injectable pen device. The dose window on the pen displays a setting of 1.8 mg. This image is related to the administration of SOGROYA (somapacitan-beco) injection, solution for subcutaneous use.*

FDA Label Image

Image 73

An anatomical illustration highlighting common subcutaneous injection sites on the human body, including the arms, abdomen, buttocks, and thighs. Markings indicate preferred areas for injection administration relevant to the drug's subcutaneous route.*

FDA Label Image

Image 74

An instructional illustration showing a hand holding a SOGROYA injection pen. The thumb is positioned on the injector button, and a downward arrow indicates pressing the pen downwards to inject. This diagram demonstrates the proper technique for subcutaneous administration of the somapacitan-beco injection solution device.*

FDA Label Image

Image 75

Instructional illustration showing a hand holding an injection pen with a caption to count slowly from 1 to 6. The image likely demonstrates part of the administration technique for subcutaneous injection using the device.*

FDA Label Image

Image 76

An instructional illustration showing a blue upward arrow pointing to the knob or plunger area of a subcutaneous injection device, likely indicating the direction to pull or activate part of the injector mechanism. The lower part shows the tip or needle area of the device.*

FDA Label Image

Image 77

Instructional diagram showing a hand twisting the cap off a prefilled injection device, likely for subcutaneous administration. An inset illustrates the cap removal direction with an arrow. The device appears designed for precise dosing, consistent with SOGROYA injection use.*

FDA Label Image

Image 78

FDA Label Image

Image 79

FDA Label Image

Image 80

Instructional illustration showing hands holding a SOGROYA injection device, demonstrating the removal of the cap by pulling it off in the indicated direction. The image is part of user guidance for administering the subcutaneous injection solution.*

FDA Label Image

Image 81

FDA Label Image

Image 82

Illustration showing a close-up of a pen injector for SOGROYA (somapacitan-beco) injection, with visible pen scale markings numbered 1 to 3 and an example label indicating approximately 1 mg left in the pen reservoir.*

FDA Label Image

Image 83

An instructional illustration showing hands holding and rotating the dial of a SOGROYA (somapacitan-beco) injection pen. The dial display indicates the dosage, with an example reading of 1.7 mg remaining. The image demonstrates how to adjust or monitor the dose level on the subcutaneous injection device.*

FDA Label Image

Image 84

FDA Label Image

Image 85

SOGROYA 5 mg injection pen with somapacitan-beco as the active ingredient, available as a subcutaneous injection solution. The label indicates administration of 5 mg per 1.5 mL (3.3 mg/mL) strength with dosing once each week. The device and label display Novo Nordisk as the manufacturer.*

FDA Label Image

Image 86

FDA Label Image

Image 87

FDA Label Image

Image 88

Packaging label for Sogroya 5 mg prefilled pen injection, containing somapacitan-beco 3.3 mg/mL in a 1.5 mL prefilled pen for subcutaneous use. The label displays the product name, strength, dosage form, dosing frequency ('once weekly'), and includes an image of the prefilled pen. The labeler is Novo Nordisk.*

FDA Label Image

Image 89

Packaging label for SOGROYA (somapacitan-beco) injection, 10 mg/1.5 mL (6.7 mg/mL) prefilled pen by Novo Nordisk. The label indicates subcutaneous injection use, single-patient use, and dosing increments of 0.05 mg for a total of 10 mg. The package shows a yellow and blue prefilled pen and instructions for once-weekly dosing.*

FDA Label Image

Image 90

An illustration showing a yellow injection pen's dose window with a scale marked at 2, 4, and 6 units, and an example dose display indicating approximately 2 mg left. The image visually explains the pen scale for the drug dose measurement.*

FDA Label Image

Image 91

An instructional illustration showing a person using a SOGROYA injection pen. It highlights the dosage window on the pen, indicating how to read the remaining dose (example shown as 2.8 mg left) on the digital display. The injection pen is designed for subcutaneous administration of somapacitan-beco.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.